Is Padcev covered by Medicare?

Yes. Padcev (J9177) is covered under Medicare Part B as a physician-administered drug when billed for a medically necessary indication. There is no drug-specific Local Coverage Determination (LCD) for it, so coverage is determined per medical necessity by your MAC; the FDA-approved indications below are the starting point.

What diagnoses are covered for Padcev (J9177)?

Medicare does not publish a drug-specific covered-diagnosis list for J9177. The 12 ICD-10 codes on this page are the FDA-approved indications — the labeled uses Medicare will generally pay for under medical necessity. Off-label uses may be covered if supported by an approved compendium.

Which Medicare policy covers Padcev?

No drug-specific LCD or Billing & Coding Article exists for Padcev. It's covered under the general Medicare Part B drug benefit per medical necessity, as judged by your Medicare Administrative Contractor (MAC).

Why was my Padcev claim denied as not medically necessary?

The most common cause is a diagnosis the MAC doesn't consider medically necessary for J9177. Bill a covered/FDA-approved indication from the list below, document medical necessity, and confirm any local guidance with your MAC.

Padcev (J9177) Medicare Coverage & FDA Indications

Page reviewed Jun 29, 2026 · from FDA-approved labeling (Drugs@FDA) — no drug-specific Medicare LCD

Quick answer

Medicare benefit

Part B (physician-administered)

FDA-indicated diagnoses

12 ICD-10 codes

Governing policy

FDA indications (no LCD)

Contractor (MAC)

Per medical necessity

Source

FDA labeling

Page reviewed

Jun 29, 2026

HCPCS codes covered:
J9177

No drug-specific Medicare coverage article exists for Padcev. Coverage is decided per medical necessity by your MAC. The FDA-approved indications below are the labeled uses Medicare generally pays for; an off-label use may be covered if supported by an approved compendium. Find your MAC by state →

What Medicare pays for Padcev (2026 Q2)

Once a claim carries a covered diagnosis, Medicare Part B reimburses the drug at the ASP + 6% payment limit. Current allowed amounts per billing unit:

HCPCS	Description	Per unit	Allowed (ASP + 6%)
J9177	Inj enfort vedo-ejfv 0.25mg	0.25 mg	$36.707

Source: CMS ASP Drug Pricing File, 2026 Q2. Payment = ASP + 6% per unit; multiply by units billed (watch JZ/JW wastage). Your patient's share is typically 20% after the deductible. Estimate the full cost & patient out-of-pocket →

Padcev is a physician-administered biologic billed under Medicare Part B (not the Part D pharmacy benefit). Under Part B, Medicare pays the practice for the drug (HCPCS J9177) plus its administration — but only when the claim's diagnosis (ICD-10) code supports medical necessity. Each MAC publishes the specific covered diagnoses in a Billing & Coding Article; a claim with a diagnosis outside that list is typically denied as not medically necessary (CO-50).

Covered ICD-10 diagnoses for Padcev

The 12 ICD-10 codes below are the FDA-approved indications for J9177 — the labeled uses Medicare generally pays for under medical necessity — grouped by condition. Use the filter to find a specific code or condition.

Urothelial Carcinoma — 3 diagnoses (applies to J9177)

Neoplasms (3)

ICD-10	Covered diagnosis
C65.9	Malignant neoplasm of unspecified renal pelvis
C67.0	Malignant neoplasm of trigone of bladder
C67.9	Malignant neoplasm of bladder, unspecified

Encounter — 1 diagnoses (applies to J9177)

Factors influencing health status (1)

ICD-10	Covered diagnosis
Z51.11	Encounter for antineoplastic chemotherapy

Bladder Cancer — 8 diagnoses (applies to J9177)

Neoplasms (8)

ICD-10	Covered diagnosis
C67.1	Malignant neoplasm of dome of bladder
C67.2	Malignant neoplasm of lateral wall of bladder
C67.3	Malignant neoplasm of anterior wall of bladder
C67.4	Malignant neoplasm of posterior wall of bladder
C67.5	Malignant neoplasm of bladder neck
C67.6	Malignant neoplasm of ureteric orifice
C67.7	Malignant neoplasm of urachus
C67.8	Malignant neoplasm of overlapping sites of bladder

How to use this list when billing

Put a medically necessary, FDA-indicated diagnosis from the list above on the claim line with J9177, match the correct product code and units (check JZ/JW wastage), and document medical necessity. Because there's no drug-specific LCD, coverage is judged per medical necessity by your MAC; an off-label use can still be covered if supported by an approved drug compendium.

LCD vs. Billing & Coding Article vs. NCD

An LCD (Local Coverage Determination) is a MAC's policy on whether a service is reasonable and necessary in its region, and its companion Billing & Coding Article holds the covered ICD-10 and HCPCS code lists. A NCD (National Coverage Determination), where one exists, applies nationwide. Padcev has no drug-specific LCD or Article, so there is no published covered-code list — it's covered under the general Part B drug benefit per medical necessity, and the FDA-approved indications above are the practical starting point.

Common Padcev denial reasons

What you see	Why	Fix
CO-50 — not medically necessary	Diagnosis the MAC doesn’t accept as medically necessary	Bill a medically necessary FDA-indicated diagnosis from the list above; document necessity (compendium cite for off-label)
Diagnosis/units mismatch	Right dx but wrong product code or unit count	Match the J/Q code and units to the drug actually given (check JZ/JW wastage)
Off-label denial	Indication isn't FDA-labeled and isn't compendium-supported	Cite an approved compendium (e.g. DrugDex/NCCN) or appeal with literature
Self-administered (SAD) denial	Drug is on your MAC's self-administered exclusion list	Check the SAD list — it may be Part D, not Part B

Frequently asked questions

Is Padcev covered by Medicare?: Yes. Padcev (J9177) is covered under Medicare Part B as a physician-administered drug when billed for a medically necessary indication. There is no drug-specific Local Coverage Determination (LCD) for it, so coverage is determined per medical necessity by your MAC; the FDA-approved indications below are the starting point.
What diagnoses are covered for Padcev (J9177)?: Medicare does not publish a drug-specific covered-diagnosis list for J9177. The 12 ICD-10 codes on this page are the FDA-approved indications — the labeled uses Medicare will generally pay for under medical necessity. Off-label uses may be covered if supported by an approved compendium.
Which Medicare policy covers Padcev?: No drug-specific LCD or Billing & Coding Article exists for Padcev. It's covered under the general Medicare Part B drug benefit per medical necessity, as judged by your Medicare Administrative Contractor (MAC).
Why was my Padcev claim denied as not medically necessary?: The most common cause is a diagnosis the MAC doesn't consider medically necessary for J9177. Bill a covered/FDA-approved indication from the list below, document medical necessity, and confirm any local guidance with your MAC.

Related references

Covered is only half the answer.

You know the diagnosis is payable. Now quote the patient before the visit and catch underpayments: get Padcev's exact Medicare allowed amount, your payer's rate vs. ASP+6%, and the patient's out-of-pocket — in about 30 seconds, free.

Estimate Padcev cost & patient owe →

Source & verification

Source: FDA-approved indications (Drugs@FDA labeling) mapped to ICD-10-CM. No drug-specific Medicare LCD/Article exists for Padcev — Part B coverage is determined per medical necessity by your MAC.
CMS article last revised: n/a — the most recent revision CMS has published for this article.
Page last reviewed by CareCost: Jun 29, 2026 (coverage data retrieved 2026-06-28; we re-verify against CMS quarterly).
Code licensing: ICD-10-CM codes are public domain (CMS/CDC). CPT® codes are AMA-copyrighted and are intentionally not listed here — see the administration-code reference for those.
Not advice: This is general billing reference, not legal or billing advice. Always verify against the LCD/Article that applies to your MAC and patient.
How we build this: Compiled programmatically from the CMS Coverage API and reviewed by the CareCost Estimate editorial team against the source article. See our methodology and editorial policy.
Spotted an error?: Email editorial@carecostestimate.com.